Diagnosis before NIA AA The impact of FDG PET in. Diagnosis after NIA AA Neuropathology and PET image 2015/10/16

Similar documents
Neuro degenerative PET image from FDG, amyloid to Tau

DISCLOSURES. Objectives. THE EPIDEMIC of 21 st Century. Clinical Assessment of Cognition: New & Emerging Tools for Diagnosing Dementia NONE TO REPORT

FDG-PET e parkinsonismi

Form D1: Clinician Diagnosis

Neuropathology of Neurodegenerative Disorders Prof. Jillian Kril

FRONTOTEMPORAL DEGENERATION: OVERVIEW, TRENDS AND DEVELOPMENTS

Dementia Update. October 1, 2013 Dylan Wint, M.D. Cleveland Clinic Lou Ruvo Center for Brain Health Las Vegas, Nevada

Round table: Moderator; Fereshteh Sedaghat, MD, PhD Brain Mapping in Dementias and Non-invasive Neurostimulation

Dementia Update. Daniel Drubach, M.D. Division of Behavioral Neurology Department of Neurology Mayo Clinic Rochester, Minnesota

FTD basics! Etienne de Villers-Sidani, MD!

Imaging of Alzheimer s Disease: State of the Art

212 Index C-SB-13,

Update on functional brain imaging in Movement Disorders

review of existing studies on ASL in dementia Marion Smits, MD PhD

DEMENTIA 101: WHAT IS HAPPENING IN THE BRAIN? Philip L. Rambo, PhD

Role of TDP-43 in Non-Alzheimer s and Alzheimer s Neurodegenerative Diseases

Yin-Hui Siow MD, FRCPC Director of Nuclear Medicine Southlake Regional Health Centre

NIH Public Access Author Manuscript Semin Neurol. Author manuscript; available in PMC 2014 November 14.

PET ligands and metabolic brain imaging Prof. Karl Herholz

Dementia and Healthy Ageing : is the pathology any different?

Mild Cognitive Impairment (MCI)

Parkinson e decadimento cognitivo. Stelvio Sestini

Non Alzheimer Dementias

Differential Diagnosis

Regulatory Challenges across Dementia Subtypes European View

Objectives. Objectives continued: 3/24/2012. Copyright Do not distribute or replicate without permission 1

Introduction, use of imaging and current guidelines. John O Brien Professor of Old Age Psychiatry University of Cambridge

Cerebral correlates of psychotic syndromes in neurodegenerative diseases

Neuroimaging Biomarkers of Neurodegenerative Diseases and Dementia

Dementia: A Comprehensive Update Neuroimaging, CSF, and genetic biomarkers in dementia

Brain imaging for the diagnosis of people with suspected dementia

Ahmadul Kadir MD. Thesis for doctoral degree (Ph.D.) 2007

I do not have any disclosures

Confronting the Clinical Challenges of Frontotemporal Dementia

Type 2 Diabetes and Brain Disease in Older Adults. Erin L. Abner, PhD, MPH Asst. Professor University Of Kentucky

Perspectives on Frontotemporal Dementia and Primary Progressive Aphasia

Visual Rating Scale Reference Material. Lorna Harper Dementia Research Centre University College London

Improving diagnosis of Alzheimer s disease and lewy body dementia. Brain TLC October 2018

! slow, progressive, permanent loss of neurologic function.

Dementia Past, Present and Future

Part 2: Early detection, assessment and treatment in relation to the new guidelines. Christopher Patterson McMaster University

Imaging in Dementia:

Dementia. Jeanette Norden, Ph.D. Professor Emerita Vanderbilt University School of Medicine

Moving Targets: An Update on Diagnosing Dementia in the Clinic

Clinicopathologic and genetic aspects of hippocampal sclerosis. Dennis W. Dickson, MD Mayo Clinic, Jacksonville, Florida USA

What s New in Dementia?

Dementia. Amber Eker, MD. Assistant Professor Near East University Department of Neurology

Dementia spectrum disorders: lessons learnt from decades with PET research

The frontotemporal dementia spectrum what the general physician needs to know Dr Jonathan Rohrer

Do not copy or distribute without permission. S. Weintraub, CNADC, NUFSM, 2009

DEMENTIA 9/29/16. Introduction. Introduction. Signs and Symptom. Epidemiology. Dementia. Dr. Yotin Chinvarun M.D. Ph.D.

Objectives. RAIN Difficult Diagnosis 2014: A 75 year old woman with falls. Case History: First visit. Case History: First Visit

3/7/2017. Alzheimer s and Dementia Research: An Advanced Discussion. Alzheimer s and Dementia Research: An Advanced Discussion

Assessment at the bedside or in the clinic using the history, examination and laboratory tests to distinguish between different types of dementia

What if it s not Alzheimer s? Update on Lewy body dementia and frontotemporal dementia

Il ruolo di nuove tecniche di imaging per la diagnosi precoce di demenza

Synaptic changes in dementia: links to cognition and behaviour

Claims & Underwriting. You already told us that story! Maria C. Carrillo, Ph.D. Sr. Director, Medical & Scientific Relations Alzheimer s Association

A Fresh View of Cognitive Disorders in Older Adults: New Classification and Screening Strategies

PHYSIOLOGY of LIMBIC SYSTEM

USE OF BIOMARKERS TO DISTINGUISH SUBTYPES OF DEMENTIA. SGEC Webinar Handouts 1/18/2013

Lecture 42: Final Review. Martin Wessendorf, Ph.D.

White matter hyperintensities correlate with neuropsychiatric manifestations of Alzheimer s disease and frontotemporal lobar degeneration

Pathogenesis of Degenerative Diseases and Dementias. D r. Ali Eltayb ( U. of Omdurman. I ). M. Path (U. of Alexandria)

Provider Led Entity. CDI Quality Institute PLE Neurocognitive Disorders AUC 02/05/2019

Diffusion Tensor Imaging in Dementia. Howard Rosen UCSF Department of Neurology Memory and Aging Center

OLD AGE PSYCHIATRY. Dementia definition TYPES OF DEMENTIA. Other causes. Psychiatric disorders of the elderly. Dementia.

Il processo diagnostico dell Alzheimer dalla clinica al neuroimaging Giovanni B. Frisoni M.D.

Frontotemporal Dementia: Towards better diagnosis. Frontotemporal Dementia. John Hodges, NeuRA & University of New South Wales, Sydney.

Stephen Salloway, M.D., M.S. Disclosure of Interest

Prof Tim Anderson. Neurologist University of Otago Christchurch

The added value of the IWG-2 diagnostic criteria for Alzheimer s disease

Imaging biomarkers for Parkinson s disease

Pharmacological Treatments for Neuropsychiatric Symptoms in Dementia 3/22/2018

Secondary prevention of Alzheimer s dementia: neuroimaging contributions

Multimodality Imaging of Alzheimer Disease and Other Neurodegenerative Dementias

Dr Fiona Kumfor University of Sydney

Dementia and Alzheimer s disease

8/14/2018. The Evolving Concept of Alzheimer s Disease. Epochs of AD Research. Diagnostic schemes have evolved with the research

Dementia and Delirium: A Neurologist s Approach to Altered Mental Status. Case 1 4/7/11. Which of the following evaluations is your next step?

Assessing and Managing the Patient with Cognitive Decline

2016 Programs & Information

Diagnosing Dementia: Signs & symptoms, differential diagnosis of common dementias, and non-degenerative memory loss

BEHAVIOURAL AND PSYCHOLOGICAL SYMPTOMS IN DEMENTIA

Alzheimer's Disease An update on diagnostic criteria & Neuropsychiatric symptoms. l The diagnosis of AD l Neuropsychiatric symptoms l Place of the ICT

Dementia. Stephen S. Flitman, MD Medical Director 21st Century Neurology

Facility IBA 18/9 Cyclotron Accelerates p and d. Facility GMP Grade Clean Room Automated Dispenser Synthera Rig FDG 07/11/2014

WHAT IS DEMENTIA? An acquired syndrome of decline in memory and other cognitive functions sufficient to affect daily life in an alert patient

Neuroimaging for dementia diagnosis. Guidance from the London Dementia Clinical Network

Diagnosis and Treatment of Alzhiemer s Disease

Altered proteins in the aging brain

Differential Diagnosis of Alzheimer s Disease and Other Types of Dementia with Development of Neuroimaging Techniques (PET, SPECT, and MRI)

What APS Workers Need to Know about Frontotemporal, Lewy Body and Vascular Dementias

Chronic Traumatic Encephalopathy Provider and Parent Essentials

DEMENTIA? 45 Million. What is. WHAT IS DEMENTIA Dementia is a disturbance in a group of mental processes including: 70% Dementia is not a disease

Dementia: It s Not Always Alzheimer s

Clinical classification of dementias, particularly in

Caring Sheet #11: Alzheimer s Disease:

Frontotemporal dementia:

Overview of neurological changes in Alzheimer s disease. Eric Karran

Transcription:

The impact of FDG PET in degenerative dementia diagnosis Jung Lung, Hsu MD, Ph.D (Utrecht) Section of dementia and cognitive impairment Department of Neurology Chang Gung Memorial Hospital, Linkou, Taipei 台灣臨床失智症學會 2015 年會 13:30 14:20 Diagnosis before NIA AA 2011 Degenerative dementia Alzheimer s dementia Fronto temporal lobar degeneration: behavior variant FTD Dementia with Lewy bodies (DLB) MCI concept, CIND, etc Diagnosis after NIA AA 2011 Degenerative dementia Alzheimer s disease dementia Amnestic variant Visuospatial variant (PCA) Frontal variant (fv AD) Fronto temporal lobar degeneration: behavior variant FTD Primary progressive aphasia Semantic variant, Progressive nonfluent variant, logopenic variant Dementia with Lewy bodies (DLB) MCI: early and late MCI due to Alzheimer s disease Preclinical s of Alzheimer s disease. Clinical degenerativ e dementia diagnosis Biomarkers support clinical diagnosis Gold standard Biomarkers improve the diagnostic accuracy Memory domain AD NIA AA criteria Behavior/Language domain FTLD FTLD criteria Parkinsonism/Visual hallucination DLB DLB criteria Biomarkers (use NIA AA criteria as example): Aβ deposition: CSF Aβ 42, amyloid PET imaging Neuronal injury: CSF tau, hippocampus volume or medial temporal atrophy by MR, FDG PET imaging Neuropathological diagnosis for degenerative dementia AD: A β plaque, neurofibrillary tangle FTLD: TDP 43, tau, etc DLB: lewy body Neuropathology and PET image Disease Positive pathology Negative pathology Alzheimer s disease dementia Lewy body dementia (DLB, PDD) Synaptic loss, neuronal loss, spongiosis. Synaptic loss, neuronal loss, spongiosis. Main neurotransmitter deficit Acetylcholine (Nu. Meynert) Dopamine (dorsal motor X nucleus), Acetylcholine Metabolic dysfunction early than anatomical changes FDG MRI Fronto temporal lobar degeneration (bv FTD, PPA) Synaptic loss, neuronal loss, spongiosis. Serotonin? von Economo neurons Current PET image marker Amyloid tracer, tau tracer FDG Different hypometabolism pattern 11C MP4A, VMAT2(AV 133), R.A. Sperling et al. / Alzheimer s & Dementia 7 (2011) 280 292 1

PET imaging in neurodegenerative disease PET imaging agents for neurodegenerative diseases have a significant impact on clinical diagnosis and patient care. PET radionuclides and imaging agents: Radionuclides: 11 C: (T 18 1/2 : 20 min), F: (T 1/2 : 110 min). Imaging agents: Metabolism: 2 [ 18 F]fluoro 2 deoxy D glucose (FDG). Amyloid: flutemetamol (FPIB), florbetapir (AV 45), florbetaben (AV 1). Tau: non selective tau PET tracer (FDDNP) and selective tau PET tracer (e.g THK523, THK5105 and THK5117). Dopamine neuron: 6 fluoro [ 18 F]DOPA (FDOPA), 9 Fluoropropyl (+) DTBZ (AV 133, VMAT2 marker). Neuronal degeneration/injury Non specific marker, based on the pattern distribution. Decreased uptake in temporo parietal cortex on FDG PET. Elevated CSF tau. Disproportional atrophy of med/basal and lateral temporal lobe and medial parietal cortex on MRI. Chem. Soc. Rev., 2014, 43, 6683 Anatomical landmark and use pons region as reference Align AC PC line Occipital lobe PCC Precuneus Parietal occipital lobe FDG PET measures It represents resting state synaptic function and density. Decrease uptake (synaptic dysfunction) may due to: Altered intracellular signalling cascades. Altered mitochondria bioenergetics. Impaired neurotransmitter release. Long distance disconnection effects. In AD: local and specific brain circuit (hippocampus, entorhinal region and in the neocortex) disrupt/alter mitochondria bioenergetics cause uptake decreased. FDG decrease uptake maybe a partly amyloid independent process contribute to neuronal dysfunction. Curr Opin Neurol 2014, 27:405 413 AD case: 77 y/o male, a farmer, 6 years education. Progressive memory loss for 6 months, repeat questions. More irritable mood. MMSE 17, CDR 0.5 AD hypometabolism pattern in PET Normal: (MMSE > 28) 98% did not show cortical hypometabolism. 1% hypometabolism restricted to the PCC. AD patients: 100 99% showed a pattern of prominent parietotemporal itt and PCC hypometabolism. 1% patient showed hypometabolism restricted to the PCC. 84% AD symmetric, 10% showed more severe hypometabolism in the left hemisphere, 6% showed more severe hypometabolism in the right hemisphere. 13 % additional frontal hypometabolism, 5% occipital hypometabolism. J Nucl Med 2008; 49:390 398 2

Plaque and tangle distribution at different s of Alzheimer s disease progression (Braak staging) Spread of tau pathology follows a distinct neuroanatomical path that suggests network connectivity Braak & Tredici Acta Neuropath 2011 FDG PET in MCI Mild Moderate Severe FDG PET showed posterior cingulate region is the most prominent changes in AD and the earliest changes seen in MCI. Individuals with MCI may also present patterns of hypometabolism resembling AD, frontotemporal dementia, or dementia with Lewy bodies, and approximately 10% of MCI subjects are reported to have normal FDG PET scan. There are no established FDG PET criteria for preclinical dementia at the MCI. A. Zimny et al. / FDG PET and MR Neuroimaging in amci Different hypometabolism maps in MCI predict future outcome DLB case: 76 y/o male, progressive memory loss for 2 years, fluctuation cognition, visual hallucination. MMSE16 C. Cerami et al. / NeuroImage: Clinical 7 (2015) 187 194 3

DLB hypometabolism pattern in PET DLB pattern: 14 patients 71% showed hypometabolism in the posterior brain regions preferentially involving the OCC, parietal cortex in 21% and of the PCC in 7%. 29% parietotemporal and PCC hypometabolism more severe than the OCC, and were misclassified as AD. bilateral in 71% of the patients, more severe in the left hemisphere in 7%, and more severe in the right hemisphere in 21% of the patients. 67% mild and 75% moderate to severe DLB patients showing occipitoparietal hypometabolism. Pathological basis of cingulate island sign (CIS) In FDG PET, median value in the posterior cingulate gyrus ROI was divided by the median value in the precuneus plus cuneus ROI to derive the CIS ratio. CIS on FDG PET is not associated with fibrillar β amyloid deposition but indicates lower Braak NFT in patients t with DLB. J Nucl Med 2008; 49:390 398 J Nucl Med 2009; 50:1638 1645; Neurology 83 August 26, 2014 Lewy body dementia (LBD) Dementia with lewy bodies (DLB) Parkinson s disease dementia (PDD) Scheme of the progression pathways and s of Lewy body (LB) disorders The pathway for PD seems likely to proceed through Stage IIa (brainstem predominant) while that for ADLB passes through Stage IIb. The pathway followed by DLB is uncertain as thecurrent definition of DLB largely excludes all but the neocortical. There may be two types of ILBD, one that leads to PD and another that leads to ADLB and possibly DLB. Only PD and DLB progress to the neocortical. Acta Neuropathol. 2009 Jun;117(6):613 34. 4

Braak Staging and clinical symptoms Mild Moderate Severe Brainstem substantia nigra DA (parkinsonism) n. basalis ACh (cognitive fluctuations) locus coerleus NE (agitation) dorsal raphe 5HT (depression /anxiety) Neocortical Occipital hypometabolism visual hallucinations, parkinsonism Temporal lobe hypometabolism delusions /psychosis Orbitofrontal hypometabolism depression /anxiety Kobayashi et al., Int. J. Geriatric Psychiatry, 2009 Bv FTD case: 55 y/o male with progressive behavior disturbance, apathy, disinhibition, hyperorality, MMSE 26. FDG PET in FTLD FTLD: behavioral variant and language variant. bv FTD: behavior abnormality predominant. Language variant: semantic dementia, progressive aphasia. bv FTD: prevalent involvement of the anterior cingulate cortex, ventromedial and/or dorsolateral frontal cortex, and orbito frontal cortex as typical of the behavioral variant of frontotemporal dementia (bvftd). http://dx.doi.org/10.3174/ajnr.a3695 Bv FTD hypometabolism pattern in PET von Economo neurons in fronto insular and anterior cingulate cortex FTD pattern: 49 patients 65% patients showed a pattern of prominent frontal or temporal hypometabolism. 35 % eitherparietotemporal and PCC hypometabolism with no frontal hypometabolism or parietotemporal and PCC hypometabolism with frontal hypometabolism that was not more severe than that in the parietotemporal and PCC regions, and were misclassified as AD. J Nucl Med 2008; 49:390 398 5

Severity of atrophy for identifying the different s of FTLD Mild Moderate Severe J Mol Neurosci (2011) 45:379 383 SN/SP in different FDG PET pattern AD Sen: 99% Spe: 98% Normal AD DLB DLB Sen: 99% Spe: 71% FTD Sen: 99% Spe: 65% Sen: 71% Spe: 65% Management Impact of FDG PET in Dementia: Results from a Tertiary Center Memory Clinic FTD AD FDG PET had moderate to high impact on the diagnosis and management in 44% participants. AD PET changed the type of dementia in 15% participants p and prescription of Clinical cholinesterase inhibitors in 17% patients. Number of uncertain diagnoses reduced 11%, decreased differential diagnosis 37% and increase very probable diagnose FTD 19%. Alzheimer s & Dementia 9 (2013) 414 421 Journal of Alzheimer s Disease 42 (2014) 885 892 PET Conclusion THM FDG PET topographical uptake pattern represents different type/ degenerative dementia. Typical AD reduced uptake in the bilateral symmetric parieto temporal, posterior cingulate, precuneus areas. DLB: reduced occipital and parieto temporal p but cingulate island sign noted. Amyloid PET (AV 45): provide evidence of amyloid deposition (cerebral amyloidosis). Dopamine system (VMAT2, AV 133): provide monoamine system activity. Tau tracer: specific THK5117 for neuronal injury marker. Thanks your attention Acknowledgement: Team members of Department of Nuclear Medicine and Department of Neurology at Chang Gang Memorial Hospital. 6